MGIC Investment Corporation MTG
Composite 69/100; the shares have moved about 21% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 46/100 — a slight mark against it.
Valuation ranks 78/100 — a strong point in its favour. Balance-sheet strength ranks 78/100 — a strong point in its favour. Quality ranks 71/100 — a moderate point in its favour.
Growth ranks 46/100 — a slight mark against it.
What the company does MGIC Investment Corporation provides private mortgage insurance and risk-management solutions to U.S. mortgage lenders. Its primary insurance covers defaults, unpaid principal, and foreclosure costs, while ancillary services include contract underwriting and reinsurance.
Key financials MTG reports strong profitability metrics: ROE 14.1%, ROA 9.0%, and net margins of 59.6%. Revenue declined -3.0% YoY, but EPS grew 1.3%. The balance sheet is conservative with a debt/equity ratio of 0.13 and a current ratio of 4.96.
Stock health The stock shows robust momentum with 12-month returns of 20.96% and a 3-month gain of 13.98%. RSI(14) at 66.50 suggests it is approaching overbought territory. Dividend yield is 2.0% with a sustainable payout ratio of 18.8%.
Price vs fair value The stock trades at a **discount of 49.80%** to our fair-value estimate of 44.94 and at a **PREMIUM of 0.70%** to the analyst 12-month target of 29.80. - Q2 earnings beat estimates despite revenue miss (Zacks, 2026-07-30) - Analysts highlight strong quality metrics but note valuation headwinds (Sideravia, 65.0 overall) - Revenue decline of -3.0% weighs on near-term growth outlook (Key Financials)
Looking forward Forward P/E of 9.56 and a PEG of 0.40 suggest undemanding valuation, but growth scores (23.6) trail peers. Analysts expect stability in mortgage insurance demand, offset by premium pressure. Monitor Q3 guidance for signs of stabilization.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.